The expanded indication makes risankizumab the first IL-23 inhibitor available for pediatric patients weighing under 40kg with plaque psoriasis or psoriatic arthritis, supported by phase 3 OptIMMize ...
The interleukin 23 inhibitor was approved for treating moderate-to-severe plaque psoriasis in adults in 2019 and for active ...
Pediatric neurointerventional procedures are increasingly performed, yet antiplatelet management remains largely empirical or extrapolated from adult practice because of limited pediatric-specific ...
A mother-of-three who took her life with a shotgun had shown no suicidal intentions and "just snapped", her heartbroken family have said. The body of Rachel Chapman-Emms was found at her home in the ...
The FDA approved lebrikizumab-lbkz (EBGLYSS) for a maintenance dosing regimen of 250 mg every 8 weeks in adults and adolescents ≥12 years and ≥40 kg with moderate-to-severe atopic dermatitis, allowing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results